Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards percutaneous valve

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences will resume the 20-patient non-randomized feasibility trial of its Cribier-Edwards percutaneous aortic heart valve at three sites, the company announced Dec. 1. Edwards first started the trial in January, but stopped it in June after discovering a new retrograde delivery approach, which involves passing the valve on a catheter through the femoral vein, across the mitral valve, and into the aortic valve - a safer and simpler approach than the antegrade approach investigators had been using (1"The Gray Sheet" June 20, 2005, p. 17). The new trial will also include a larger 26 mm valve. Cases will commence upon investigational review board approval...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT022971

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel